Skip to search formSkip to main contentSkip to account menu

capmatinib

Known as: 2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide 
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Alterations in c-MET, a tyrosine kinase receptor encoded by the MET gene, have been reported in in approximately 3% of NSCLC and… 
2019
2019
Patients with non-small cell lung cancer harboring MET exon 14 skipping mutations have commonly been treated with the multikinase… 
2018
2018
AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after… 
2018
2018
The mesenchymal-epithelial transition factor (MET)/hepatocyte growth factor (HGF) axis is a key pathway in acquired resistance… 
2017
2017
BACKGROUND c-MET and PI3K pathways are dysregulated in GBM and can drive cancer growth in pre-clinical models. INC280 is a small… 
2016
2016
4074Background: Overexpression/activation of cMET occurs in 20‒48% of HCC, and predicts worse survival. Capmatinib (INC280) is a…